Results 241 to 250 of about 5,438,748 (355)

Do Moral Views Change during a Crisis? An Experiment on Health Care Priority Setting. [PDF]

Med Decis Making
Strand L, Gustavsson E, Tinghög G.
europepmc   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Top 10 research priorities for adolescent and young adult cancer in Canada: a James Lind Alliance priority setting partnership. [PDF]

BMJ Open
Tutelman PR, Thurston C, Ranger T, Rader T, Henry B, Abdelaal M, Blue M, Buckland TW, Del Gobbo S, Dobson L, Gallant E, Heykoop C, Jansen M, Larsen L, Maseja N, Oberoi S, Ramasamy V, Smith M, Wendowsky N, Beattie S, Bender JL, Birnie K, Garland SN, Jibb L, Noel M, Schulte FSM.   +25 more
europepmc   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Global Mapping and Visualization of Substance Use Disorders and Treatment: Implications for Priority Setting. [PDF]

Adv Biomed Res
Mazhari SR, Najari A, Sobhani Z, Latifi M.   +3 more
europepmc   +1 more source

High performance in healthcare priority setting and resource allocation: a literature- and case study-based framework in the Canadian context [PDF]

, 2016
Bryan, Stirling, Donaldson, Cam, Gibson, Jennifer L., Hall, William, Mitton, Craig, Peacock, Stuart, Smith, Neale, Urquhart, Bonnie   +7 more
core   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Setting research priorities for palliative and end-of-life care: a James Lind Alliance Priority Setting Partnership Refresh. [PDF]

BMJ Open
Hudson BF, Ashcroft P, Bedford J, Bush J, Bowers B, Dawson A, Hussain J, Holmes S, Kumar R, Minton O, McCullagh A, Nicoll L, Penny A, Rabbitte M, Reece A, Robinson D, Simpson-Greene C, Taylor M, Best SL.   +18 more
europepmc   +1 more source

Mapping the hotspots and coldspots of ecosystem services in conservation priority setting

Journal of Geographical Science, 2017
Yingjie Li, Liwei Zhang, Junping Yan, Pengtao Wang, Ningke Hu, W. Cheng, B. Fu   +6 more
semanticscholar   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source